🇺🇸 FDA
Pipeline program

ISIS 3521

CDR0000068686

Phase 3 mab completed

Quick answer

ISIS 3521 for Lung Cancer is a Phase 3 program (mab) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Lung Cancer
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials